ArticleNPJ digital medicine2025
Developing a thyroid cancer differentiation state classification system using deep residual networks and metabolic signature profiling.
Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
We developed a deep residual network (ResNet) framework to classify thyroid cancer differentiation states by integrating multiomic data and interpretability analysis. Our framework incorporated untargeted metabolomic, whole-exome sequencing, and transcriptomic data from 158 thyroid tumors and 57 matched normal tissues, encompassing well-differentiated, poorly differentiated, and anaplastic thyroid cancers. We further examined single-cell RNA sequencing datasets from the Gene Expression Omnibus (GEO) to map key metabolic reprogramming pathways in dedifferentiated thyroid cancer. We systematically integrated transcriptomic data from follicular epithelial-derived thyroid carcinomas across all GEO cohorts, establishing a pan-pathological classification model based on a 10-gene metabolic signature. To complement this approach, a 10-metabolite model was developed via the ResNet architecture, capitalizing on the direct pathophysiological responsiveness of metabolites to tumor progression states. By employing Shapley additive explanations, we highlighted critical metabolic signatures driving differentiation states. Our findings reveal how metabolic shifts underpin thyroid cancer progression, and based on these findings, we propose an accurate, interpretable model that may facilitate early diagnosis and inform clinical decision-making.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.